Search, find and save your favorites – Use Bayer's Quick Finder to find content that is relevant to you.

Interim Report First Quarter of 2018

Bayer: Operational business
held back by currency effects
Major progress with
Monsanto acquisition

At a glance

Selected Key Figures

Group sales

9.1 billion

+ 2.0 %

Group sales in the first quarter of 2018 rose by 2.0% (Fx & portfolio adj.) to €9,138 million (reported: – 5.6%).

EBITDA before special items

2.9 billion

5.2 %

Group EBITDA before special items was down by 5.2%, at €2,896 million.

Core earnings per share

2.28

Core earnings per share from continuing operations decreased by 1.3% to €2.28 (Q1 2017: €2.31).

Sales, Earnings and Financial Position

Business Development of the Divisions

Pharmaceuticals

Sales of Pharmaceuticals increased by 2.9% (Fx & portfolio adj.) to €4,075 million in the first quarter of 2018. Our key growth products Xarelto™, Eylea™, Xofigo™, Stivarga™ and Adempas™ once again delivered strong performance overall, with their combined sales rising by 14.1% (Fx adj.) to €1,561 million (Q1 2017: €1,445 million).

Find out more

Consumer Health

Sales of Consumer Health declined by 2.2% (Fx & portfolio adj.) in the first quarter of 2018 to €1,409 million. EBITDA before special items of Consumer Health declined by a substantial 20.2% to €313 million in the first quarter of 2018 (Q1 2017: €392 million).

Find out more

Crop Science

In the first quarter of 2018, Crop Science posted sales of €2,861 million (Fx & portfolio adj. – 1.0%), which was level with the strong prior-year quarter. EBITDA before special items of Crop Science decreased by 6.5% to €1,042 million in the first quarter of 2018 (Q1 2017: €1,115 million).

Find out more